keyword
https://read.qxmd.com/read/38646622/evaluation-of-the-in-vitro-susceptibility-of-clinical-isolates-of-ndm-producing-klebsiella-pneumoniae-to-new-antibiotics-included-in-a-treatment-regimen-for-infections
#1
JOURNAL ARTICLE
Natalia Słabisz, Patrycja Leśnik, Jarosław Janc, Miłosz Fidut, Marzenna Bartoszewicz, Ruth Dudek-Wicher, Urszula Nawrot
BACKGROUND: Due to the growing resistance to routinely used antibiotics, the search for new antibiotics or their combinations with effective inhibitors against multidrug-resistant microorganisms is ongoing. In our study, we assessed the in vitro drug susceptibility of Klebsiella pneumoniae strains producing New Delhi metallo-β-lactamases (NDM) to antibiotics included in the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommendations...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38646565/computational-and-experimental-strategies-for-combating-mbl-p-aeruginosa-mblpa-biofilms-using-phytochemicals-targeting-the-quorum-sensing-network
#2
JOURNAL ARTICLE
Maryum Fakhar, Mehboob Ahmed, Anjum Nasim Sabri
Pseudomonas aeruginosa is a Gram-negative opportunistic bacterium, ubiquitously found in nature and causative agent in many infections. Due to increased antibiotic resistance, there is a need to develop more robust antibacterial agents from natural sources. In this study, we worked on two metallo-β-lactamase (MBL) producing Pseudomonas aeruginosa strains and targeted the Quorum Sensing mechanism (QS) of these bacteria to combat antibiotic resistance. Our study aimed at using phytochemicals which have been used since centuries in herbal medicine...
June 2024: Saudi Journal of Biological Sciences
https://read.qxmd.com/read/38582880/cobalt-complexes-modulate-plasmid-conjugation-in-escherichia-coli-and-klebsiella-pneumoniae
#3
JOURNAL ARTICLE
Ilyas Alav, Parisa Pordelkhaki, Pedro Ernesto de Resende, Hannah Partington, Simon Gibbons, Rianne M Lord, Michelle M C Buckner
Antimicrobial resistance genes (ARG), such as extended-spectrum β-lactamase (ESBL) and carbapenemase genes, are commonly carried on plasmids. Plasmids can transmit between bacteria, disseminate globally, and cause clinically important resistance. Therefore, targeting plasmids could reduce ARG prevalence, and restore the efficacy of existing antibiotics. Cobalt complexes possess diverse biological activities, including antimicrobial and anticancer properties. However, their effect on plasmid conjugation has not been explored yet...
April 6, 2024: Scientific Reports
https://read.qxmd.com/read/38560541/cefepime-versus-piperacillin-tazobactam-for-the-treatment-of-intra-abdominal-infections-secondary-to-potential-ampc-beta-lactamase-producing-organisms
#4
JOURNAL ARTICLE
Kelly C Gamble, Dusten T Rose, Stephanie Y Chang, Emily K Hodge, Theresa C Jaso, Marc D Trust, Mitchell J Daley
Background: Recent studies have established cefepime as an effective treatment option for AmpC beta-lactamase (AmpC) Enterobacterales; however, the efficacy of beta-lactam/beta-lactamase inhibitors is unclear. Objective: The objective of this study was to determine if piperacillintazobactamis an appropriate alternative to cefepime for the treatment of intra-abdominal infections (IAIs) secondary to AmpC-producing organisms. Methods: This multicenter, retrospective cohort study was conducted in hospitalized adults with an IAI caused by an AmpC-producing organism and received either cefepime or piperacillin-tazobactam for definitive treatment after a source control procedure...
December 2023: Hospital Pharmacy
https://read.qxmd.com/read/38554556/development-and-validation-of-a-simple-and-affordable-lc-uv-method-for-identification-and-assay-of-selected-antimicrobial-medicines
#5
JOURNAL ARTICLE
Haile Kassahun, Ann Van Schepdael, Gebremariam Ketema, Erwin Adams
Antimicrobials, particularly antibiotics, are among the most common classes of drugs reported as substandard and falsified (SF) in developing countries. Therefore, it is important to develop simple and affordable analytical methods for the quality control of antimicrobial medicines. In this study, a liquid chromatographic method with ultraviolet detection (LC-UV) was developed and validated for the screening and quantification of 13 antimicrobial medicines and one beta-lactamase inhibitor in pharmaceutical formulations...
March 27, 2024: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/38543683/rare-plasmid-mediated-ampc-beta-lactamase-dha-1-located-on-easy-mobilized-is26-related-genetic-element-detected-in-escherichia-coli-from-livestock-and-food-in-germany
#6
JOURNAL ARTICLE
Chiara Manfreda, Annemarie Kaesbohrer, Silvia Schmoger, Tanja Skladnikiewicz-Ziemer, Mirjam Grobbel, Alexandra Irrgang
AmpC beta-lactamases cause resistance to third-generation cephalosporins, including beta-lactamase inhibitors. In Escherichia coli from the German food production chain, the majority of AmpC beta-lactamase activity can be attributed to plasmid-mediated CMY-2 or overproduction of chromosomal AmpC beta-lactamase, but occasionally other enzymes like DHA-1 are involved. This study investigated the prevalence of the AmpC beta-lactamase DHA-1 in ESBL/AmpC-producing E. coli ( n = 4706) collected between 2016 and 2021 as part of a German antimicrobial resistance monitoring program along the food chain...
March 21, 2024: Microorganisms
https://read.qxmd.com/read/38543545/first-report-and-characterization-of-a-plasmid-encoded-bla-sfo-1-in-a-multi-drug-resistant-aeromonas-hydrophila-clinical-isolate
#7
JOURNAL ARTICLE
Troy Skwor, Dan Christopher Jones, Caitlin Cahak, Ryan J Newton
Antibiotic resistance remains one of the most pressing public health issues facing the world today. At the forefront of this battle lies the ever-increasing identification of extended-spectrum beta-lactamases and carbapenemases within human pathogens, conferring resistance towards broad-spectrum and last-resort antimicrobials. This study was prompted due to the identification of a pathogenic Aeromonas hydrophila isolate (strain MAH-4) collected from abdominal fluid, which presented a robust resistance pattern against second-, third-, and fourth-generation cephalosporins, ertapenem, ciprofloxacin, gentamicin, levofloxacin and moxifloxacin, and beta lactam/beta-lactamase inhibitor combinations...
February 29, 2024: Microorganisms
https://read.qxmd.com/read/38534696/current-therapeutic-approaches-for-multidrug-resistant-and-extensively-drug-resistant-acinetobacter-baumannii-infections
#8
REVIEW
Petros Rafailidis, Periklis Panagopoulos, Christos Koutserimpas, George Samonis
The treatment of Acinetobacter baumannii infections remains a challenge for physicians worldwide in the 21st century. The bacterium possesses a multitude of mechanisms to escape the human immune system. The consequences of A. baumannii infections on morbidity and mortality, as well on financial resources, remain dire. Furthermore, A. baumannii superinfections have also occurred during the COVID-19 pandemic. While prevention is important, the antibiotic armamentarium remains the most essential factor for the treatment of these infections...
March 15, 2024: Antibiotics
https://read.qxmd.com/read/38534684/national-level-cross-sectional-study-on-antibiotic-use-in-children-during-the-pre-and-early-covid-19-eras
#9
JOURNAL ARTICLE
Ji Young Park, Hyun Mi Kang
This study aimed to investigate national data for a quantitative evaluation of antibiotic usage in Korean children during the pre- and early COVID-19 period. This was a cross-sectional study from 2016 to 2021 of children <18 years, grouped by age (0, 1, 2-4, 5-11, and 12-17 years) and city/province. Systemic antibiotic prescriptions, days of administration, and population by age and region were collected. Days of therapy (DOT)/1000 pediatric inhabitant per day (PID) was used for antibiotic quantitative monitoring...
March 9, 2024: Antibiotics
https://read.qxmd.com/read/38533260/redirecting-pantoprazole-as-a-metallo-beta-lactamase-inhibitor-in-carbapenem-resistant-klebsiella-pneumoniae
#10
JOURNAL ARTICLE
Wesam H Abdulaal, Nabil A Alhakamy, Amer H Asseri, Mohamed F Radwan, Tarek S Ibrahim, Solomon Z Okbazghi, Hisham A Abbas, Basem Mansour, Aly A Shoun, Wael A H Hegazy, Mahmoud Saad Abdel-Halim
The development of resistance to carbapenems in Klebsiella pneumoniae due to the production of metallo-β-lactamases (MBLs) is a critical public health problem because carbapenems are the last-resort drugs used for treating severe infections of extended-spectrum β-lactamases (ESBLs) producing K. pneumoniae . Restoring the activity of carbapenems by the inhibition of metallo-β-lactamases is a valuable approach to combat carbapenem resistance. In this study, two well-characterized clinical multidrug and carbapenem-resistant K...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38475927/carbapenem-resistant-hypervirulent-st23-klebsiella-pneumoniae-with-a-highly-transmissible-dual-carbapenemase-plasmid-in-chile
#11
JOURNAL ARTICLE
Matías Gálvez-Silva, Patricio Arros, Camilo Berríos-Pastén, Aura Villamil, Paula I Rodas, Ingrid Araya, Rodrigo Iglesias, Pamela Araya, Juan C Hormazábal, Constanza Bohle, Yahua Chen, Yunn-Hwen Gan, Francisco P Chávez, Rosalba Lagos, Andrés E Marcoleta
BACKGROUND: The convergence of hypervirulence and carbapenem resistance in the bacterial pathogen Klebsiella pneumoniae represents a critical global health concern. Hypervirulent K. pneumoniae (hvKp) strains, frequently from sequence type 23 (ST23) and having a K1 capsule, have been associated with severe community-acquired invasive infections. Although hvKp were initially restricted to Southeast Asia and primarily antibiotic-sensitive, carbapenem-resistant hvKp infections are reported worldwide...
March 12, 2024: Biological Research
https://read.qxmd.com/read/38455070/exploring-the-secrets-of-virus-entry-the-first-respiratory-syncytial-virus-carrying-beta-lactamase
#12
JOURNAL ARTICLE
Marcio De Ávila-Arias, Jose Luis Villarreal-Camacho, Christian Cadena-Cruz, Leidy Hurtado-Gómez, Heather M Costello, Alexander Rodriguez, Francisco Burgos-Florez, Alfonso Bettin, Meisam Naeimi Kararoudi, Amner Muñoz, Mark E Peeples, Homero San-Juan-Vergara
BACKGROUND: Respiratory Syncytial Virus (RSV) presents a significant health threat, especially to young children. In-depth understanding of RSV entry mechanisms is essential for effective antiviral development. This study introduces an innovative RSV variant, featuring the fusion of the beta-lactamase (BlaM) enzyme with the RSV-P phosphoprotein, providing a versatile tool for dissecting viral entry dynamics. METHODS: Using the AlphaFold2 algorithm, we modeled the tertiary structure of the P-BlaM chimera, revealing structural similarities with both RSV-P and BlaM...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38442544/antimicrobial-resistance-and-public-and-animal-health-risks-associated-with-pathogenic-escherichia-coli-isolated-from-calves
#13
JOURNAL ARTICLE
Dircéia Aparecida da Costa Custódio, Carine Rodrigues Pereira, Maysa Serpa Gonçalves, Anna Cecília Trolesi Reis Borges Costa, Pedro Felipe Rodrigues de Oliveira, Bruna Henrique Pinto da Silva, Giovanna Botelho Carneiro, Fernanda Morcatti Coura, Andrey Pereira Lage, Marcos Bryan Heinemann, Geraldo M Árcio da Costa, Elaine Maria Seles Dorneles
We aimed to determine the antimicrobial susceptibility profile of pathogenic Escherichia coli strains isolated from fecal samples of calves and buffalo calves (2008-2013), in Minas Gerais, Brazil, as well as the frequency of O157 gene and strains carrying extended-spectrum beta-lactamases (ESBL) and mobile colistin resistance (mcr) genes. E. coli strains (n=518) were tested for susceptibility against ten antimicrobials. Tetracycline was the antimicrobial with the highest resistance rate (382/518), followed by ampicillin (321/518), sulfamethoxazole/trimethoprim (312/518), chloramphenicol (192/518), gentamicin (126/518), ciprofloxacin (148/518), cefazolin (89/518), colistin (54/518) and cefoxitin (34/518)...
February 19, 2024: Comparative Immunology, Microbiology and Infectious Diseases
https://read.qxmd.com/read/38411995/balancing-the-scales-achieving-the-optimal-beta-lactam-to-beta-lactamase-inhibitor-ratio-with-continuous-infusion-piperacillin-tazobactam-against-extended-spectrum-beta-lactamase-producing-enterobacterales
#14
JOURNAL ARTICLE
Pier Giorgio Cojutti, Manjunath P Pai, Tommaso Tonetti, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Piperacillin/tazobactam (TZP) is administered intravenously in a fixed ratio (8:1) with the potential for inadequate tazobactam exposure to ensure piperacillin activity against Enterobacterales . Adult patients receiving continuous infusion (CI) of TZP and therapeutic drug monitoring (TDM) of both agents were evaluated. Demographic variables and other pertinent laboratory data were collected retrospectively. A population pharmacokinetic approach was used to select the best kidney function model predictive of TZP clearance (CL)...
February 27, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38384586/phenotypic-and-genotypic-characterization-of-extended-spectrum-beta-lactamase-producing-clinical-isolates-of-escherichia-coli-and-klebsiella-pneumoniae-in-two-kenyan-facilities-a-national-referral-and-a-level-five-hospital
#15
JOURNAL ARTICLE
Sylvia M Maveke, Gabriel O Aboge, Laetitia W Kanja, Alfred O Mainga, Naftaly Gachau, Beatrice W Muchira, Gervason A Moriasi
BACKGROUND: The emergence of antimicrobial resistance (AMR) and multidrug resistance (MDR) among Escherichia coli and Klebsiella pneumoniae , especially through the production of extended spectrum β -lactamases (ESBLs), limits therapeutic options and poses a significant public health threat. OBJECTIVE: The aim of this study was to assess the phenotypic and genetic determinants of antimicrobial resistance of ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates from patient samples in two Kenyan Hospitals...
2024: International Journal of Microbiology
https://read.qxmd.com/read/38381581/antibiotic-resistance-a-global-crisis-problems-and-solutions
#16
REVIEW
Rupesh Aggarwal, Pooja Mahajan, Sameeksha Pandiya, Aayushi Bajaj, Shailendra Kumar Verma, Puja Yadav, Arun S Kharat, Asad Ullah Khan, Meenakshi Dua, Atul Kumar Johri
Healthy state is priority in today's world which can be achieved using effective medicines. But due to overuse and misuse of antibiotics, a menace of resistance has increased in pathogenic microbes. World Health Organization (WHO) has announced ESKAPE pathogens ( Enterococcus faecium , Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) as the top priority pathogens as these have developed resistance against certain antibiotics. To combat such a global issue, it is utmost important to identify novel therapeutic strategies/agents as an alternate to such antibiotics...
February 21, 2024: Critical Reviews in Microbiology
https://read.qxmd.com/read/38375685/a-real-world-pharmacovigilance-study-of-ceftazidime-avibactam-data-mining-of-the-food-and-drug-administration-adverse-event-reporting-system-database
#17
JOURNAL ARTICLE
Haiping Yao, Yanyan Wang, Yan Peng, Zhixiong Huang, Guoping Gan, Zhu Wang
Ceftazidime/avibactam (CAZ/AVI) is a combination of a well-known third-generation, broad-spectrum cephalosporin with a new beta-lactamase inhibitor that has been approved for the treatment of various infectious diseases (especially multidrug-resistant Gram-negative bacterial infections) by the Food and Drug Administration (FDA). The current study extensively assessed CAZ/AVI-related adverse events (AEs) in the real world through data mining of the FDA Adverse Event Reporting System (FAERS) database to better understand toxicities...
February 20, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38354826/activity-of-aztreonam-avibactam-against-enterobacterales-resistant-to-recently-approved-beta-lactamase-inhibitor-combinations-collected-in-europe-latin-america-and-the-asia-pacific-region-2020-2022
#18
JOURNAL ARTICLE
Helio S Sader, Cecilia G Carvalhaes, John H Kimbrough, Rodrigo E Mendes, Mariana Castanheira
Aztreonam-avibactam is under clinical development for treatment of infections caused by carbapenem-resistant Enterobacterales (CRE), especially those resistant to recently approved β-lactamase inhibitor combinations (BLICs). We evaluated a large collection of CRE isolates, including those nonsusceptible to ceftazidime-avibactam, meropenem-vaborbactam, and/or imipenem-relebactam. Overall, 24,580 Enterobacterales isolates were consecutively collected (1/patient) in 2020-2022 from 64 medical centres located in Western Europe (W-EU), Eastern Europe (E-EU), Latin America (LATAM), and the Asia-Pacific region (APAC)...
February 12, 2024: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/38329330/comprehensive-stability-analysis-of-13-%C3%AE-lactams-and-%C3%AE-lactamase-inhibitors-in-in-vitro-media-and-novel-supplement-dosing-strategy-to-mitigate-thermal-drug-degradation
#19
JOURNAL ARTICLE
Jieqiang Zhou, Yuli Qian, Yinzhi Lang, Yongzhen Zhang, Xun Tao, Bartolome Moya, Alaa R M Sayed, Cornelia B Landersdorfer, Eunjeong Shin, Carolin Werkman, Nicholas M Smith, Tae Hwan Kim, Monika Kumaraswamy, Beom Soo Shin, Brian T Tsuji, Robert A Bonomo, Richard E Lee, Jürgen B Bulitta
Non-clinical antibiotic development relies on in vitro susceptibility and infection model studies. Validating the achievement of the targeted drug concentrations is essential to avoid under-estimation of drug effects and over-estimation of resistance emergence. While certain β-lactams (e.g., imipenem) and β-lactamase inhibitors (BLIs; clavulanic acid) are believed to be relatively unstable, limited tangible data on their stability in commonly used in vitro media are known. We aimed to determine the thermal stability of 10 β-lactams and 3 BLIs via LC-MS/MS in cation-adjusted Mueller Hinton broth at 25 and 36°C as well as agar at 4 and 37°C, and in water at -20, 4, and 25°C...
February 8, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38319508/reduced-susceptibility-to-aztreonam-avibactam-conferred-by-acquired-ampc-type-%C3%AE-lactamases-in-pbp3-modified-escherichia-coli
#20
JOURNAL ARTICLE
Nicolas Helsens, Mustafa Sadek, Christophe Le Terrier, Laurent Poirel, Patrice Nordmann
PURPOSE: Carbapenemase-producing Enterobacterales are a growing threat, and very few therapeutic options remain active against those multidrug resistant bacteria. Aztreonam is the molecule of choice against metallo-beta-lactamases (MBL) producers since it is not hydrolyzed by those enzymes, but the co-production of acquired plasmidic cephalosporinases or extended-spectrum β-lactamases leading to aztreonam resistance may reduce the efficacy of this molecule. Hence, the development of the aztreonam-avibactam (AZA) combination provides an interesting therapeutic alternative since avibactam inhibits the activity of both cephalosporinases and extended-spectrum β-lactamases...
February 6, 2024: European Journal of Clinical Microbiology & Infectious Diseases
keyword
keyword
120533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.